BIOVECTRA and Revolution Biomanufacturing announced a strategic partnership to offer integrated mRNA sequence optimization and end‑to‑end GMP manufacturing. Revolution brings proprietary UTR/codon optimization tools and AI‑driven sequence engineering that reportedly increase protein expression 3‑ to 5‑fold; BIOVECTRA supplies clinical‑scale plasmid, mRNA, LNP, and sterile drug‑product manufacturing. The alliance aims to reduce development friction for mRNA therapeutics and accelerate transfers to clinic, addressing a common bottleneck where design improvements fail to translate quickly to GMP production.